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ABSTRACT
Background: Leukotriene receptor antagonists (LTRAs) are effective for prophylactic treatment of pollinosis
based on studies showing that administration of LTRAs prior to or at the start of the pollen season reduces
symptoms and QOL disturbance at the peak of pollen dispersal. Two goals of prophylactic treatment of pollino-
sis are use of fewer types of drugs and delay of onset of symptoms and impairement of QOL. Therefore, this
study was performed to determine if pranlukast, a LTRA, met these goals in treatment of pollinosis.
Methods: Pranlukast or placebo was administered to patients who visited our hospital immediately before the
start of Japanese cedar pollen dispersal. The study was performed for 4 weeks as a double blind randomized
trial. Subsequently, all patients were given pranlukast for a further 4 weeks from the peak until the end of pollen
dispersal. The incidence of symptoms and use of concomitant drugs were investigated from daily nasal allergy
records kept by patients. QOL was evaluated using the JRQLQ questionnaire.
Results: In the double blind period of the study, the percentage of patients who used concomitant drugs for
nasal symptoms was significantly lower in the pranlukast group compared to the placebo group. Development
of nasal symptoms (sneezing, runny nose and nasal congestion) and disturbance of daily activities were signifi-
cantly delayed in the pranlukast group. No serious adverse reactions occurred in the pranlukast group and no
patient withdrew from treatment with pranlukast.
Conclusions: Pranlukast is effective for prophylactic treatment of pollinosis.
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INTRODUCTION
Japanese cedar pollinosis is a seasonal allergic rhini-
tis that has been increasing in prevalence since it was
first reported in 1964.1 The disease is specific to Ja-
pan and many patients are found in areas from Kanto
to Tokai District along the Pacific Ocean due to the
plantation of cedar after the end of World War II. The
prevalence of Japanese cedar pollinosis in 2008 was
26.5% across Japan and 32.1% in Tokyo, the area of
this study, and has increased by approximately 10%
over the past 10 years.2 The dispersal of Japanese ce-
dar pollen begins in early February, reaches a peak
from late February to mid-March, and ends in late
March. Patients with Japanese cedar pollinosis often
have severe nasal and eye symptoms, which impair
their quality of life (QOL) and social productivity.3
Therefore, it is important to treat patients prior to or
at the start of pollen dispersal to prevent pollinosis
symptoms in the peak dispersal season. Based on
these criteria, the Japanese clinical guidelines for na-
sal allergy recommend early pharmacotherapy for pa-
tients with pollinosis.4
Leukotriene receptor antagonists (LTRAs) reduce
cysteinylleukotriene (cysLT)-induced vasodilation5
and vascular hyperpermeability6 in the nasal mucosa
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and are effective for nasal congestion.7,8 CysLTs also
stimulate release of inflammatory cells, including
eosinophils and macrophages,9,10 and LTRAs are ef-
fective for allergic inflammation caused by these cells
in patients with perennial allergic rhinitis.11 Many
clinical studies have shown that LTRAs have a similar
effect to antihistamines in patients with pollinosis.12-14
Overseas15 and Japanese16,17 studies have shown that
LTRA administration prior to or in the early period of
pollen dispersal reduces symptoms during pollen dis-
persal. Prophylactic treatment of pollinosis should be
performed with a minimum number of different types
of drugs and the therapy should delay the onset of
symptoms and impairment of QOL. In this study, we
evaluated the efficacy of pranlukast, a LTRA, for pro-
phylactic treatment of pollinosis based on these crite-
ria.
METHODS
SUBJECTS
The subjects were patients with Japanese cedar polli-
nosis who lived in Tokyo and surrounding areas. The
inclusion criteria were an age of 20-65 years old, a
positive result (eruption diameter 10 mm) in the
antigen-specific dermal test for standard Japanese ce-
dar pollen extracts (Torii Pharmaceutical Co., Tokyo,
Japan), or a serum Japanese cedar-specific IgE level
2 in a CAP radioallergosorbent test (SRL Inc., To-
kyo, Japan). The exclusion criteria were complication
with nasal polyp, acutechronic rhinitis, or sinusitis; a
requirement for continuous administration of antihis-
tamines, antiallergic drugs or a steroid nasal spray;
current immunotherapy; pregnantlactating women,
or patients who planned to become pregnant; or per-
sons judged by a physician to be inappropriate from
an efficacy and safety perspective. After a full explana-
tion of the study and expected adverse reactions was
given, informed consent was obtained from each pa-
tient. This study was conducted in Nippon Medical
School Hospital in accordance with the Helsinki Dec-
laration (2000) and ethical guidelines for clinical tri-
als, after approval of the Nippon Medical School Hos-
pital Ethics Committee.
STUDY PROTOCOL
Pranlukast hydrate (112.5 mg) or placebo in a cap-
sule was used in the study. The placebo and 112.5 mg
pranlukast capsule were confirmed to be indistin-
guishable by the controller of the study. Subjects who
had given consent were allocated to placebo and
pranlukast groups at random. This was done in
groups of six patients, with three placed in the pla-
cebo group and three in the pranlukast group, with-
out bias in sex and age. At the end of January 2007,
89 patients (41 in the placebo group and 48 in the
pranlukast group) with a skin test positive for Japa-
nese cedar pollen were selected among the 97 partici-
pants who had initially been allocated to the groups.
In accordance with the study schedule shown in Fig-
ure 1, pranlukast or placebo was administered from
February 4. Patients took 2 capsules orally twice a
day after breakfast and supper for 4 weeks (double
blind study period). Subsequently, all patients were
given pranlukast for 4 weeks (pranlukast treatment
period).
From two weeks after the start of the study, the pa-
tients were allowed treatment based on their own
judgment and in accordance with the clinical guide-
lines for nasal allergy. Thus, patients were allowed to
use an antihistamine (loratadine, 1 tabletday), a
vasoconstrictor nasal spray (tetrahydrozoline hydro-
chloride, up to 2 sprays in each nostrilday for no
more than 7 continuous days), and cromolyn sodium
eye drops (up to 4 drops in each eye) during and af-
ter the second half of the double blind study period.
During the pranlukast administration period (Fig. 1),
patients were also allowed to use these drugs and a
steroid nasal spray (fluticasone propionate), again
based on the severity of symptoms and their own
judgment.
The test products were capsules containing pla-
cebo or pranlukast (112.5 mg) and were verified to be
indistinguishable from each other by the study con-
troller. Patients were randomly assigned to the pran-
lukast or placebo group (3 patientsgroup, 6 patients
set) by the controller without bias in sex and age.
Japanese cedar pollen was detected using a Durham
pollen sampling device in Chiyoda-ku, Tokyo and the
amount of dispersed Japanese cedar pollen was ob-
tained from data published by the Bureau of Social
Welfare and Public Health, Tokyo Metropolitan Gov-
ernment.
EVALUATION
The patients completed daily records of nasal allergy
diary and answered the Japanese Rhinoconjunctivitis
Quality of Life Questionnaire (JRQLQ) every 2 weeks
until the end of the study. Nasal symptoms were
evaluated from the nasal allergy diary. Paroxysmal
sneezing (frequency of sneezing per day), runny
nose (frequency of nose blowing per day), nasal con-
gestion, and disturbance of daily activities were evalu-
ated on a 5-point scale (0-4) using Okuda’s modified
classification. A mean weekly score was calculated for
each symptom and for disturbance of daily activities.
A score that increased by at least 1 compared to the
score in week 1 was taken to indicate the presence of
a symptom or worsening of disturbance in daily ac-
tivities. The percentage of patients who did not need
a concomitant drug was also determined from the
daily nasal allergy records. The QOL items of the
JRQLQ and overall conditions based on the face scale
were rated on a 5-point scale (0-4). A score that was at
least 1 point higher than the score at the start of the
study was taken to indicate impairment of QOL or of
overall conditions.
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Fig.　1　Study schedule and the amount of cedar pollen dispersed in 2007.
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STATISTICAL ANALYSIS
Data analysis was conducted using chi-square and
log-rank tests with two-tailed distributions and a sig-
nificance level of 5%, using SAS v. 8.02 (Cary, NC,
USA).
RESULTS
AMOUNT OF CEDAR POLLEN DISPERSAL
As shown in Figure 1, pollen dispersal in 2007 started
on February 6 (2 days after the start of administra-
tion) and the amount of cedar pollen exceeded 20
cm2day almost daily for 3 weeks from February 19
to March 11. Pollen gradually decreased from March
12 onwards and was rarely detected on April 1 and
thereafter. The total amount of cedar pollen from
February 4 to March 31 was 1329cm2.18
SUBJECTS
Of the initial 89 patients, 87 completed the study and
2 were omitted: one due to pregnancy and the other
due to withdrawal of agreement. The placebo group
consisted of 39 patients (22 males, 17 females, age
35.8 ± 12.4 years old) and the pranlukast group in-
cluded 48 patients (30 males, 18 females, age 36.7 ±
11.4 years old). The rates of perennial allergic rhinitis
were 35.9% and 27.1% in the placebo and pranlukast
groups, respectively. There was no significant differ-
ence in sex, age, age of incidence, duration of disor-
der, and frequency of perennial allergic rhinitis be-
tween the two groups (Table 1).
THERAPEUTIC EFFECT
Onset of sneezing, runny nose and nasal congestion,
and disturbance of daily activities were significantly
delayed in the pranlukast group compared with the
control group (Fig. 2). The rates of appearance of
sneezing, runny nose, and nasal congestion and dis-
turbance of daily activities were significantly lower in
the pranlukast group compared to the placebo group
at the end of the double blind period and at the end of
the study (χ2-test and data not shown). Use of con-
comitant antihistamines, steroid nasal spray, and cro-
molyn sodium eye drops showed similar courses in
the pranlukast and placebo groups, but the use of a
vasoconstrictor nasal spray was significantly delayed
in the pranlukast group compared with the placebo
group (Fig. 3). In the 4-week double blind study, a
significantly higher percentage of patients in the
pranlukast group did not need a concomitant nasal
Gotoh M et al.
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Table　1　Patient backgrounds
The placebo group
(n = 39)
The pranlukast group
(n = 48) p-value
Sex (males/females) 22/17 30/18 0.565 (χ2-test)
Age (years, mean ± S.D.) 35.8 ± 12.4 36.7 ± 11.4 0.720 (t-test)
Age at onset (years, mean ± S.D.) 23.7 ± 9.7 25.4 ± 9.2 0.407 (t-test)
Duration of disease (years, mean ± S.D.) 12.1 ± 8.3 11.5 ± 8.7 0.771 (t-test)
Perennial allergic rhinitis (Complication ratio) 14 (35.9) 13 (27.1) 0.377 (χ2-test)
Fig.　2　Changes in the percentage of patients without nasal symptoms or disturbance of daily activities. 
The mean weekly score was calculated for each symptom and for disturbance of daily activities. A patient 
with a score that increased by at least 1 from the score in the 1st week was defi ned as having the symp-
tom or worsening of disturbance in daily activities.
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drug (68.8% (3348) vs. 38.5% (939), p = 0.0050, χ2-
test).
With regard to QOL, worsening of scores for eight
out of 17 JRQLQ items (disturbance in study, work
and housekeeping, poor concentration, reduced
thinking, disturbance in reading newspaperbooks,
memory decline, disturbance in outdoor activities
such as sports and picnics, malaise, and fatigue) and
for overall conditions were significantly delayed in
the pranlukast group compared with the placebo
group (Fig. 4). Deterioration of 8 QOL items and the
items summarized above were significantly lower in
the pranlukast group compared to the placebo group
at the end of the double blind period and at the end of
the study (χ2-test and data not shown).
Few patients had new symptoms or newly deterio-
rated QOL in either group after the end of the double
blind period. Moreover, the rates of appearance of
symptoms and deterioration of QOL changed simi-
larly in the two groups after the end of the double
blind period.
ADVERSE REACTIONS
Two patients in the pranlukast group had adverse re-
actions. Soft feces occurred 16 days after the start of
administration in one patient. The symptom was re-
lieved by 2-day withdrawal and administration of an
intestinal regulator, and subsequently pranlukast was
resumed and administered continuously. Abdominal
pain developed 16 days after the start of administra-
Prophylactic Treatment of Japanese Cedar Pollinosis
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Fig.　3　Changes in the percentage of patients who did not 
need vasoconstrictor nasal spray. The use of vasoconstrictor 
nasal spray was determined from the daily records of nasal 
allergy kept by the patients.
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Fig.　4　Changes in the percentage of patients who showed no worsening of QOL and overall conditions. The QOL domains of 
the JRQLQ and overall conditions based on the face scale were rated on a 5-point scale (0-4). A patient with a score that in-
creased by at least 1 from the score at the start of the study was defi ned as having worsening of QOL or worsening of overall 
conditions.
Disturbance of study, work and housekeeping
p < 0.001
(%)
100
80
60
40
20
0
0 2 4 6 8(weeks)
Poor concentration
p = 0.005
(%)
(weeks)
Reduced thinking
p = 0.006
(%)
(weeks)
Disturbance of reading newspapers/books
p = 0.003
(%)
(weeks)
Memory decline  
p = 0.002
(%)
(weeks)
Disturbance of outdoor activities
p = 0.026
(%)
(weeks)
p = 0.010
(%)
(weeks)
Fatigue
p = 0.045
(%)
(weeks)
Overall conditions
p = 0.018
(%)
(weeks)
Malaise
(Log ranktest)
Pranlukast group
Placebo group
100
80
60
40
20
0
0 2 4 6 8
Pranlukast group
Placebo group
100
80
60
40
20
0
0 2 4 6 8
Pranlukast group
Placebo group
100
80
60
40
20
0
0 2 4 6 8
Pranlukast group
Placebo group
100
80
60
40
20
0
0 2 4 6 8
Pranlukast group
Placebo group
100
80
60
40
20
0
0 2 4 6 8
Pranlukast group
Placebo group
100
80
60
40
20
0
0 2 4 6 8
Pranlukast group
Placebo group
100
80
60
40
20
0
0 2 4 6 8
Pranlukast group
Placebo group
100
80
60
40
20
0
0 2 4 6 8
Pranlukast group
Placebo group
tion in another patient, and disappeared 2 days later
without the withdrawal of pranlukast.
DISCUSSION
Several studies have proposed the hypothesis of
“minimal persistent inflammation” in allergic rhini-
tis,19,20 with repeated exposure to antigens at a low
level (that does not induce symptoms in a single ex-
posure) suggested to cause persistent nasal inflam-
mation. Patients with seasonal allergic rhinitis are re-
peatedly exposed to antigens at one-hundredth the
level that induces symptoms in the off-season, and
this causes increased histamine and ECP concentra-
tions in nasal discharge.21 Furthermore, IL-1, leukot-
riene and ECP in nasal discharge remain high even
after improvement of symptoms to preseason levels
at 6 weeks after the end of the pollen season.22 The
hypothesis of ”minimal persistent inflammation” sug-
gests that administration of antiinflammatory drugs
to patients with pollinosis prior to or in the early pe-
riod of pollen dispersal is important for inhibition of
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symptoms and minimization of QOL disturbance in
the pollen dispersal season.
Several placebo-controlled comparative studies
have shown the efficacy of treatment of pollinosis
with LTRAs in the early season based on nasal symp-
tom and QOL scores; i.e., these scores in the treated
group were better than those in the placebo
group.13-15 In prophylactic treatment of pollinosis, it is
important to delay the onset of nasal symptoms and
QOL impairment, and it is also better to treat patients
with fewer kinds of drugs. Thus, in this study we
evaluated the appropriateness of pranlukast for pro-
phylactic treatment of pollinosis based on these crite-
ria. Prophylactic treatment with pranlukast was found
to delay onset of nasal symptoms, including sneezing,
runny nose and nasal congestion, and disturbance of
QOL, as evaluated with a QOL questionnaire specific
to allergic rhinitis. During the double blind study pe-
riod, rhinitis was treated effectively with pranlukast
alone in approximately 70% of patients. Consequently,
we suggest that pranlukast is appropriate for prophy-
lactic treatment of pollinosis.
Only a small number of patients developed new
symptoms or showed deteriorated QOL in the pranlu-
kast and placebo groups after the end of the double
blind period. The rate of appearance of symptoms
and the rate of deterioration of QOL were similar in
the two groups after the end of the double blind pe-
riod.
We believe that these results reflect the effect of
use of pranlukast in the two groups after the end of
the double blind period, in addition to the effects of
combination drugs (especially nasal steroids). Steroid
nasal spray is the most effective drug for allergic
rhinitis,23,24 but compliance is sometimes poor and
many Japanese patients prefer oral drugs.25 A combi-
nation of an antihistamine and a LTRA has been
shown to have a similar effect to steroid nasal spray
on daytime nasal symptoms,26 and the combination
therapy may be an option for patients with poor com-
pliance.
Although this study was a small-scale trial, our re-
sults show that prophylactic treatment with pranlu-
kast, a LTRA, delayed the incidence of nasal symp-
toms, worsening of QOL, and use of concomitant
drugs. A large-scale comparative trial of the effect of a
combination of an antihistamine and LTRA with that
of a steroid nasal spray during pollen dispersal is re-
quired to confirm these findings. However, we con-
clude that LTRAs are appropriate drugs for prophy-
lactic treatment of Japanese cedar pollinosis.
ACKNOWLEDGEMENTS
We appreciate the advice of Drs. Minoru Okuda, Aki-
yoshi Konno, Yoshitaka Okamoto and Peary L. Orga,
and the assistance of Dr. Hidenori Suzuki, who
served as the controller of the trial, and Mr. Tatsu-
yuki Kakuma, the biological statistician. This work
was supported by the Japan Allergy Foundation.
CONFLICT OF INTEREST
No potential conflict of interest was disclosed.
REFERENCES
1. Horiguchi S, Saito Y. [Discovery of Japanese cedar polli-
nosis in Nikko, Ibaraki prefecture]. Arerugi 1964;13:16-8
(in Japanese).
2. Murayama K, Baba K, Okubo K. [Regional differences in
the prevalence of Japanese cedar-pollen allergy]. Arerugi
2010;59:47-54(in Japanese).
3. Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M,
Crawford B. Fexofenadine improves the quality of life and
work productivity in Japanese patients with seasonal aller-
gic rhinitis during the peak cedar pollinosis season. Int
Arch Allergy Immunol 2005;136:148-54.
4. [Practical Guidelines for the Management of Allergic Rhini-
tis in Japan: Perennial Rhinitis and Pollinosis], 6th edn.
Tokyo: Life Science Publishing, 2009(in Japanese).
5. Mizutani N, Nabe T, Imai A, Sakurai H, Takenaka H,
Kohno S. Markedly increased nasal blockage by intrana-
sal leukotriene D4 in an experimental allergic rhinitis
model: contribution of dilated mucosal blood vessels. Jpn
J Pharmacol 2001;86:170-82.
6. Shirasaki H, Kojima T, Asakura K, Kataura A, Shimamoto
K, Iimura O. The pathophysiological role of kinin and
chemical mediators on experimental allergic rhinitis. Adv
Exp Med Biol 1989;247A:375-8.
7. Lipworth BJ. Emerging role of antileukotriene therapy in
allergic rhinitis. Clin Exp Allergy 2001;31:1813-21.
8. Meltzer EO. Clinical evidence for antileukotriene therapy
in the management of allergic rhinitis. Ann Allergy
Asthma Immunol 2002;88(Suppl 1):23-9.
9. Oshima N, Nagase H, Koshino T et al. A functional study
on CysLT(1) receptors in human eosinophils. Int Arch Al-
lergy Immunol 2002;129:67-75.
10. Thivierge M, Stankova J, Rola-Plerszczynski M. IL-13 and
IL-4 upregulate cysteinyl leukotriene 1 receptor expres-
sion in human monocytes and macrophages. J Immunol
2001;167:2855-60.
11. Ueda T, Takeno S, Furukido K, Hirakawa K, Yajin K. Leu-
kotriene receptor antagonist pranlukast suppresses
eosinophil infiltration and cytokine production in human
nasal mucosa of perennial allergic rhinitis. Ann Otol Rhi-
nol Laryngol 2003;112:955-61.
12. Philip G, Malmstrom K, Hampel FC et al. Montelukast for
treating seasonal allergic rhinitis: a randomized, double-
blind, placebo-controlled trial performed in the spring.
Clin Exp Allergy 2002;32:1020-8.
13. Van Adelsberg J, Philip G, Pedinoff AJ et al. Montelukast
improves symptoms of seasonal allergic rhinitis over a 4-
week treatment period. Allergy 2003;58:1268-76.
14. Meltzer EO, Philip G, Weinstein SF et al. Montelukast ef-
fectively treats the nighttime impact of seasonal allergic
rhinitis. Am J Rhinol 2005;19:591-8.
15. Kurowski M, Kuna P, Gorski P. Montelukast plus cetiriz-
ine in the prophylactic treatment of seasonal allergic
rhinitis: influence on clinical symptoms and nasal allergic
inflammation. Allergy 2004;59:280-8.
16. Sasaki K, Okamoto Y, Yonekura S et al. Cedar and cy-
press pollinosis and allergic rhinitis: Quality of life effects
of early intervention with leukotriene receptor antago-
nists. Int Arch Allergy Immunol 2009;149:350-8.
17. Yonekura S, Okamoto Y, Okubo K et al. Beneficial effects
Prophylactic Treatment of Japanese Cedar Pollinosis
Allergology International Vol 60, No4, 2011 www.jsaweb.jp 489
of leukotriene receptor antagonists in the prevention of
cedar pollinosis in a community setting. J Investig Allergol
Clin Immunol 2009;19:195-203.
18. Bureau of Social Welfare and Public Health, Tokyo Met-
ropolitan Government. [Data for Japanese Cedar Pollen].
Available at: http:www.fukushihoken.metro.tokyo.jpkan
hokafunkousinsugi.html(in Japanese).
19. Storms WW. Minimal persistent inflammation, an emerg-
ing concept in the nature and treatment of allergic rhini-
tis: the possible role of leukotrienes. Ann Allergy Asthma
Immunol 2003;91:131-40.
20. Canonica GW, Compalati E. Minimal persistent inflamma-
tion in allergic rhinitis: implications for current treatment
strategies. Clin Exp Immunol 2009;158:260-71.
21. Roquat A, Ihre E, van Hage-Hamsten M, Halldén G, Zet-
terström O. Allergen-induced inflammation in the nose: a
comparison of acute and repeated low-dose allergen expo-
sure. Allergy 1996;51:42-8.
22. Bachert C, van Kempen M, van Cauwenberge P. Regula-
tion of proinflammatory cytokines in seasonal allergic
rhinitis. Int Arch Allergy Immunol 1999;118:375-9.
23. Bhatia S, Baroody FM, DeTineo M, Naclerio RM. In-
creased nasal airflow with budesonide compared with
desloratadine during the allergy season. Arch Otolaryngol
Head Neck Surg 2005;131:223-8.
24. Berger WE, Nayak AS, Staudinger HW. Mometasone fu-
roate improves congestion in patients with moderate-to-
severe seasonal allergic rhinitis. Ann Pharmacother 2005;
39:1984-9.
25. Okuda M, Ohkubo K, Gotoh M, Ishida Y. [Treatment of
Japanese cedar pollinosis and its impact on patients satis-
faction]. Arerugi 2004;53:596-600(in Japanese).
26. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of
monotherapy with intra-nasal corticosteroid or combined
oral histamine and leukotriene receptor antagonists in
seasonal allergic rhinitis. Clin Exp Allergy 2001;31:61-8.
